CNS Demyelination with TNF-[alpha] Blockers

Tumor necrosis factor-[alpha] (TNF-[alpha]) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- [alpha] blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively...

Full description

Saved in:
Bibliographic Details
Published in:Current neurology and neuroscience reports 2017, Vol.17 (4), p.1
Main Authors: Kemanetzoglou, Elissavet, Andreadou, Elisabeth
Format: Review
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor-[alpha] (TNF-[alpha]) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- [alpha] blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side effects associated with immune suppression have been reported, including central and peripheral nervous system (CNS) demyelinating disorders. It is still elusive whether these events are mere coincidence or a side effect of anti-TNF-[alpha] use. In this paper, we review the published case reports of CNS demyelination associated with anti-TNF-[alpha] therapy and present the follow-up of our 4 previously reported patients who developed neurologic symptoms suggestive of CNS demyelination after having received anti-TNF-[alpha] treatment. We also discuss the possible role of TNF-[alpha] blockers in demyelination.
ISSN:1528-4042
1534-6293